Mar 09, 2019
Information Update - Multiple Losartan-containing drugs voluntarily recalled because of potential for nitrosamine impurity
Mar 04, 2019
PDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
Jan 11, 2019
Bernstein Liebhard LLP Evaluating Potential Valsartan Lawsuits for Cancer and Liver Injuries Allegedly Caused by Contaminated Heart and Blood Pressure Medications
Nov 08, 2018
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Oct 04, 2018
ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets
Aug 20, 2018
/R E P E A T -- Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution/
Jul 13, 2018
FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity
Jul 10, 2018
Update - Advisory - Several drugs containing valsartan being recalled due to contamination with a potential carcinogen
Jul 09, 2018
Advisory - Several drugs containing valsartan being recalled due to contamination with a potential carcinogen
Jun 06, 2018
Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Aug 01, 2017
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation